Skip to content

In 2022, we expect sales and earnings development in our business segments as shown in the table below:

Financial Targets by Business Segment 2022

Download(XLS, 36 KB)
  Targets 20221 Fiscal year 20212
Fresenius Medical Care3    
Sales growth (in constant currency) Low-to-mid single-digit percentage growth €17,619 m
Net income4 growth (in constant currency) Low-to-mid single-digit percentage growth €1,018 m
Fresenius Kabi    
Sales growth (organic) Low single-digit percentage growth €7,193 m
EBIT growth (in constant currency) Decline in high single- to low double-digit percentage range €1,153 m
Fresenius Helios    
Sales growth (organic) Low-to-mid single-digit percentage growth €10,891 m
EBIT growth (in constant currency) Mid single-digit percentage growth €1,127 m
Fresenius Vamed    
Sales growth (organic) High single- to low double-digit percentage growth €2,297 m
EBIT Returning to absolute pre-COVID levels (2019: € 134 m) €101 m
1 Before special items, including expected COVID-19 effects
2 Before special items, including COVID-19 effects 
3 These targets are based on the 2021 results excluding the costs related to FME25 of €49 million (for Net Income). They are based on the outlined assumptions, in constant currency and 
exclude special items. Special items include further costs related to FME25 and other effects 
that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at 
the time of giving guidance. 
4 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA